Market LIVE
Published markets; coverage varies by country
Product profile · United States

POTASSIUM CHLORIDE

 ·  Patent Litigation & Settlement History ↓

IngredientPOTASSIUM CHLORIDE
Application typeNDA
Application208019
Product001
Dosage formFOR SOLUTION
RouteORAL
Strength20MEQ
Approval date2015-08-19
Marketing statusPrescription
Status event—
ApplicantGENUS
Product source

Current GenericRadar decision

Year2017
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2017-10-23
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2017-10-23
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
209662 / 001FINAL_APPROVAL · FINAL_APPROVED2017-10-23—UPSHER SMITH LABORATORIES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210241 / 001FINAL_APPROVAL · FINAL_APPROVED2018-11-21—NOVEL LABORATORIES INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210200 / 001FINAL_APPROVAL · FINAL_APPROVED2018-11-23—EPIC PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212183 / 001FINAL_APPROVAL · FINAL_APPROVED2019-05-06—AJENAT PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210902 / 001FINAL_APPROVAL · FINAL_APPROVED2019-05-23—AMNEAL PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211667 / 001FINAL_APPROVAL · FINAL_APPROVED2021-03-11—STRIDES PHARMA GLOBAL PTE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213467 / 001FINAL_APPROVAL · FINAL_APPROVED2022-01-27—GRANULES PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214108 / 001FINAL_APPROVAL · FINAL_APPROVED2022-03-24—RUBICON RESEARCH LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212816 / 001FINAL_APPROVAL · FINAL_APPROVED2023-07-12—NOVITIUM PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
219009 / 001FINAL_APPROVAL · FINAL_APPROVED2025-07-11—ADAPTIS PHARMA PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 10 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
209662 / 001UPSHER SMITH LABORATORIES LLCFINAL_APPROVAL · FINAL_APPROVED2017-10-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210241 / 001NOVEL LABORATORIES INCFINAL_APPROVAL · FINAL_APPROVED2018-11-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210200 / 001EPIC PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2018-11-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212183 / 001AJENAT PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2019-05-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210902 / 001AMNEAL PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2019-05-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211667 / 001STRIDES PHARMA GLOBAL PTE LTDFINAL_APPROVAL · FINAL_APPROVED2021-03-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213467 / 001GRANULES PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2022-01-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214108 / 001RUBICON RESEARCH LTDFINAL_APPROVAL · FINAL_APPROVED2022-03-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212816 / 001NOVITIUM PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2023-07-12 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
219009 / 001ADAPTIS PHARMA PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2025-07-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2017-10-23TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.